Chondrial Therapeutics, Inc., is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases. Our mission is to develop therapies for diseases that are rare and where there is an unmet medical need. We are initially targeting Friedreich’s Ataxia (FA), which is a progressive disease that affects multiple body systems, particularly the brain and heart. FA is the most common ataxia in man and is caused by a deficiency of a key protein, frataxin, which is normally present in the mitochondria of all tissues. Children and young adults progressively lose the ability to walk and speak, and their hearts become very thick and weak, and can eventually fail. There is currently no cure for FA.
Scope of the position
Chondrial is anticipating the Director/Senior Director of Clinical Operations will be a key member of the senior management team. The position will play an important role in execution of the clinical development of CTI-1601, Chondrial’s lead drug candidate, as well as the clinical development of new pipeline compounds.
The Director/Senior Director of Clinical Operations will be responsible for the following activities: